title: 1,5-anhydro-D-fructose and its derivatives: biosynthesis, preparation and potential medical applications.
abstract: 1,5-Anhydro-D-fructose (AF) was first found in fungi and red algae. It is produced by the degradation of glycogen, starch and maltosaccharides with α-1,4-glucan lyase (EC 4.2.2.13). In vivo, AF is metabolized to 1,5-anhydro-D-glucitol (AG), ascopyrone P (APP), microthecin and other derivatives via the anhydrofructose pathway. The genes coding for the enzymes in this pathway have been cloned, enabling the large-scale production of AF and related products in a cell-free reactor. The possible applications of these products in medicine have been evaluated using both in vitro and in vivo systems. Thus AF is a useful anticariogenic agent as it inhibits the growth of the oral pathogen Streptococcus mutans, impairing the production of plaque-forming polysaccharides and lactic acid. AF also shows anti-inflammatory and anticancer effects. AG is used as a diabetic marker for glycemic control. AG also stimulates insulin secretion in insulinoma cell lines. in vivo, APP has been shown to lengthen the life span of cancer-afflicted mice. It interferes with tumor growth and metastasis by its cidal effects on fast multiplying cells. Microthecin inhibits the growth of the human pathogen Pseudomonas aeruginosa PAO1, particularly under anaerobic conditions. The pharmaceutical usefulness of the other AF metabolites 1,5-anhydro-D-mannitol,1-deoxymannojirimycin, haliclonol, 5-epipentenomycin I, bissetone, palythazine, isopalythazine, and clavulazine remains to be investigated. In this review AF and its metabolites as the bioactive natural products for their pharmaceutical potentials are discussed.
authors.affiliation: Department of Medicine, Unit of Emergency Medicine, Karolinska Institute, Huddinge, Stockholm, Sweden. roland.fiskesund@ki.se
authors.forename: Roland
authors.initials: R
authors.lastname: Fiskesund
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Abeyama
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Yoshinaga
authors.forename: Jun-ichi
authors.initials: J
authors.lastname: Abe
authors.forename: Yongbing
authors.initials: Y
authors.lastname: Yuan
authors.forename: Shukun
authors.initials: S
authors.lastname: Yu
mesh_terms: D000818:Animals; D000890:Anti-Infective Agents / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D000975:Antioxidants / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D050260:Carbohydrate Metabolism; D003731:Dental Caries / Q000517:prevention & control; D005632:Fructose / Q000031:analogs & derivatives* / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D007661:Ketoses / Q000378:metabolism / Q000494:pharmacology; D051379:Mice; D020011:Protective Agents / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D051381:Rats
chemical_list: D000890:Anti-Infective Agents; D000970:Antineoplastic Agents; D000975:Antioxidants; D007328:Insulin; D007661:Ketoses; D020011:Protective Agents; C118494:microthecin; D005632:Fructose; C048927:1,5-anhydrofructose